164 related articles for article (PubMed ID: 35614430)
1. Failure of crizotinib based systemic treatment in ALK positive histiocytosis involving the central nervous system: a case report and literature review.
He Q; Zhang W; Li Q
BMC Pediatr; 2022 May; 22(1):308. PubMed ID: 35614430
[TBL] [Abstract][Full Text] [Related]
2. ALK-rearranged histiocytosis: Report of two cases with involvement of the central nervous system.
Rossi S; Gessi M; Barresi S; Tamburrini G; Giovannoni I; Ruggiero A; Colafati GS; Frassanito P; Carboni A; Alexandre A; Cacchione A; Trombatore P; Diomedi-Camassei F; Gaspari S; Gianno F; Marras CE; Cecinati V; Carai A; Mastronuzzi A; Alaggio R
Neuropathol Appl Neurobiol; 2021 Oct; 47(6):878-881. PubMed ID: 34048085
[TBL] [Abstract][Full Text] [Related]
3. Distinct Clinicopathologic Features and Possible Pathogenesis of Localized ALK-positive Histiocytosis of the Breast.
Osako T; Kurisaki-Arakawa A; Dobashi A; Togashi Y; Baba S; Shiozawa S; Ishigame H; Ishige H; Ohno S; Ishikawa Y; Takeuchi K
Am J Surg Pathol; 2022 Mar; 46(3):344-352. PubMed ID: 34482333
[TBL] [Abstract][Full Text] [Related]
4. Case Report: ALK-Positive Histiocytosis With
Guo Y; Qu HB; Ning G; Jia FL; Liu H; Ma XM; Liao Y
Front Oncol; 2022; 12():858939. PubMed ID: 35359354
[TBL] [Abstract][Full Text] [Related]
5. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion.
Chang KTE; Tay AZE; Kuick CH; Chen H; Algar E; Taubenheim N; Campbell J; Mechinaud F; Campbell M; Super L; Chantranuwat C; Yuen ST; Chan JKC; Chow CW
Mod Pathol; 2019 May; 32(5):598-608. PubMed ID: 30573850
[TBL] [Abstract][Full Text] [Related]
6. Local ALK-Positive Histiocytosis With Unusual Morphology and Novel
Tran TAN; Chang KTE; Kuick CH; Goh JY; Chang CC
Int J Surg Pathol; 2021 Aug; 29(5):543-549. PubMed ID: 33243034
[TBL] [Abstract][Full Text] [Related]
7. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
[TBL] [Abstract][Full Text] [Related]
8. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.
Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880
[TBL] [Abstract][Full Text] [Related]
9. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nishio M; Nakagawa K; Mitsudomi T; Yamamoto N; Tanaka T; Kuriki H; Zeaiter A; Tamura T
Lung Cancer; 2018 Jul; 121():37-40. PubMed ID: 29858024
[TBL] [Abstract][Full Text] [Related]
10. Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib.
Zhou Y; Hurtado-Castillo M; Pandey O
Front Med (Lausanne); 2023; 10():1288849. PubMed ID: 38093982
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
[TBL] [Abstract][Full Text] [Related]
12. Expanding the Phenotype of ALK-positive Histiocytosis: A Report of 2 Cases.
Huang H; Gheorghe G; North PE; Suchi M
Pediatr Dev Pathol; 2018; 21(5):449-455. PubMed ID: 29224419
[TBL] [Abstract][Full Text] [Related]
13. ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.
Syrykh C; Ysebaert L; Péricart S; Evrard SM; Meggetto F; Kanoun S; Brousset P; Laurent C
Virchows Arch; 2021 Apr; 478(4):779-783. PubMed ID: 33011863
[TBL] [Abstract][Full Text] [Related]
14. Multisystem ALK-positive histiocytosis: a multi-case study and literature review.
Liu W; Liu HJ; Wang WY; Tang Y; Zhao S; Zhang WY; Yan JQ; Liu WP
Orphanet J Rare Dis; 2023 Mar; 18(1):53. PubMed ID: 36915094
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic lymphoma kinase-positive histiocytosis with multisystem involvement: A case report.
Tu Y; Lu Y
Pediatr Dermatol; 2024; 41(3):551-553. PubMed ID: 38346136
[TBL] [Abstract][Full Text] [Related]
16. ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology.
Kashima J; Yoshida M; Jimbo K; Izutsu K; Ushiku T; Yonemori K; Yoshida A
Am J Surg Pathol; 2021 Mar; 45(3):347-355. PubMed ID: 32826530
[TBL] [Abstract][Full Text] [Related]
17. Impact of ALK Inhibitors in Patients With
Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223
[TBL] [Abstract][Full Text] [Related]
18. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.
Kemps PG; Picarsic J; Durham BH; Hélias-Rodzewicz Z; Hiemcke-Jiwa L; van den Bos C; van de Wetering MD; van Noesel CJM; van Laar JAM; Verdijk RM; Flucke UE; Hogendoorn PCW; Woei-A-Jin FJSH; Sciot R; Beilken A; Feuerhake F; Ebinger M; Möhle R; Fend F; Bornemann A; Wiegering V; Ernestus K; Méry T; Gryniewicz-Kwiatkowska O; Dembowska-Baginska B; Evseev DA; Potapenko V; Baykov VV; Gaspari S; Rossi S; Gessi M; Tamburrini G; Héritier S; Donadieu J; Bonneau-Lagacherie J; Lamaison C; Farnault L; Fraitag S; Jullié ML; Haroche J; Collin M; Allotey J; Madni M; Turner K; Picton S; Barbaro PM; Poulin A; Tam IS; El Demellawy D; Empringham B; Whitlock JA; Raghunathan A; Swanson AA; Suchi M; Brandt JM; Yaseen NR; Weinstein JL; Eldem I; Sisk BA; Sridhar V; Atkinson M; Massoth LR; Hornick JL; Alexandrescu S; Yeo KK; Petrova-Drus K; Peeke SZ; Muñoz-Arcos LS; Leino DG; Grier DD; Lorsbach R; Roy S; Kumar AR; Garg S; Tiwari N; Schafernak KT; Henry MM; van Halteren AGS; Abla O; Diamond EL; Emile JF
Blood; 2022 Jan; 139(2):256-280. PubMed ID: 34727172
[TBL] [Abstract][Full Text] [Related]
19. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
20. Benefit of crizotinib in a lung cancer patient with discordant ALK testing results.
Grocholski S; Banerji S; Qing G; Dawe DE
Cancer Treat Res Commun; 2018; 15():13-16. PubMed ID: 30207282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
